📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: InflaRx

1.1 - Company Overview

InflaRx Logo

InflaRx

Headquarter: Germany
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of therapeutics for acute and chronic inflammation targeting the C5a/C5aR pathway, including vilobelimab, a monoclonal antibody for chronic inflammatory diseases, oncology and critically ill COVID-19, authorized for emergency use by the FDA in hospitalized adults requiring invasive mechanical ventilation or ECMO, and INF904, an oral C5aR inhibitor in development for chronic spontaneous urticaria and hidradenitis suppurativa.

Products and services

  • Vilobelimab: Authorized for emergency use by the FDA to treat COVID-19 in hospitalized adults requiring invasive mechanical ventilation or ECMO
  • Vilobelimab: Monoclonal antibody targeting C5a, applied in chronic inflammatory diseases, oncology, and critically ill COVID-19 patients
  • INF904: Orally administered small molecule C5aR inhibitor being developed for chronic inflammatory conditions, specifically chronic spontaneous urticaria and hidradenitis suppurativa

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to InflaRx

Frame Therapeutics Logo

Frame Therapeutics

HQ: The Netherlands Website
  • Description: Provider of DNA-based cancer vaccines tailored to the unique characteristics of each patient's tumor, aiming to transform cancer treatment by directing the immune system toward Frame neoantigens.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Frame Therapeutics company profile →
Crescendo Biologics Logo

Crescendo Biologics

HQ: United Kingdom Website
  • Description: Provider of Humabody VH-based antibody therapeutics and a discovery platform enabling rapid discovery of fully human VH domains for small, stable multi-specifics. Offerings include CB307 (PSMA x CD137 bispecific in trial for metastatic castration-resistant prostate cancer), CB213 (preclinical PD-1 x LAG-3), and ZL-1102 (topical IL-17A; licensed to Zai Lab). Also engages in partnered and licensed programs with BioNTech, Takeda.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Crescendo Biologics company profile →
GlobeImmune Logo

GlobeImmune

HQ: United States Website
  • Description: Provider of a proprietary Tarmogen® platform used to develop products for the treatment of cancer and infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GlobeImmune company profile →
Onyvax Logo

Onyvax

HQ: United Kingdom Website
  • Description: Provider of cancer therapies that harness the immune system’s selective power to seek out and destroy tumor cells, specifically targeting cancer cells to improve effectiveness while minimizing side effects compared to conventional treatments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Onyvax company profile →
MolMed Logo

MolMed

HQ: Italy Website
  • Description: Provider of medical biotechnology research, development and clinical validation of novel anticancer therapies. The pipeline includes antitumour therapeutics in clinical and preclinical development, including Zalmoxis (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MolMed company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for InflaRx

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to InflaRx

2.2 - Growth funds investing in similar companies to InflaRx

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for InflaRx

4.2 - Public trading comparable groups for InflaRx

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to InflaRx

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About InflaRx

What does InflaRx do?

InflaRx is a provider of therapeutics for acute and chronic inflammation targeting the C5a/C5aR pathway, including vilobelimab, a monoclonal antibody for chronic inflammatory diseases, oncology and critically ill COVID-19, authorized for emergency use by the FDA in hospitalized adults requiring invasive mechanical ventilation or ECMO, and INF904, an oral C5aR inhibitor in development for chronic spontaneous urticaria and hidradenitis suppurativa.

Who are InflaRx's competitors?

InflaRx's competitors and similar companies include Frame Therapeutics, Crescendo Biologics, GlobeImmune, Onyvax, and MolMed.

Where is InflaRx headquartered?

InflaRx is headquartered in Germany.

How many employees does InflaRx have?

InflaRx has 1,000 employees 🔒.

When was InflaRx founded?

InflaRx was founded in 2010 🔒.

What sector and industry vertical is InflaRx in?

InflaRx is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for InflaRx

Who are the top strategic acquirers in InflaRx's sector and industry

Top strategic M&A buyers and acquirers in InflaRx's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for InflaRx?

Top strategic M&A buyers groups and sectors for InflaRx include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in InflaRx's sector and industry vertical

Which are the top PE firms investing in InflaRx's sector and industry vertical?

Top PE firms investing in InflaRx's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in InflaRx's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in InflaRx's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in InflaRx's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to InflaRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in InflaRx's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for InflaRx?

The key public trading comparables and valuation benchmarks for InflaRx include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for InflaRx for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for InflaRx with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in InflaRx's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for InflaRx with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in InflaRx's' sector and industry vertical?

Access recent funding rounds and capital raises in InflaRx's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for InflaRx